BINEX Co., Ltd. (KOSDAQ:053030)
South Korea · Delayed Price · Currency is KRW 14,220
+400 (2.89%)
Nov 20, 2025, 3:30 PM KST
BINEX Revenue
BINEX had revenue of 44.53B KRW in the quarter ending June 30, 2025, with 41.49% growth. This brings the company's revenue in the last twelve months to 153.18B, up 19.39% year-over-year. In the year 2024, BINEX had annual revenue of 130.05B, down -16.00%.
Revenue (ttm)
153.18B
Revenue Growth
+19.39%
P/S Ratio
2.87
Revenue / Employee
244.70M
Employees
626
Market Cap
440.13B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 130.05B | -24.77B | -16.00% |
| Dec 31, 2023 | 154.82B | -1.85B | -1.18% |
| Dec 31, 2022 | 156.68B | 22.28B | 16.58% |
| Dec 31, 2021 | 134.40B | 1.42B | 1.07% |
| Dec 31, 2020 | 132.98B | 7.72B | 6.16% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 5.50T |
| Celltrion | 3.75T |
| Yuhan | 2.17T |
| Hanmi Pharm. | 1.50T |
| SK Biopharmaceuticals | 620.28B |
| Sam Chun Dang Pharm. | 215.10B |
| ALTEOGEN | 158.06B |
| LigaChem Biosciences | 148.28B |